5 results
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
The primary objective of the study is to perform a set of hypothesis-driven analyses on the study data set, aiming to correlate established biomarkers (obtained clinically, from brain MRI, from CSF, from known genetic factors, and from monitoring of…
The first objective is to validate novel digital biomarkers for disease progression in de novo Parkinson*s disease patients. The biomarkers can eventually serve as a primary clinical endpoint in additional future clinical studies. As part of this…
Primary Objective: To evaluate the long-term safety (including progression to acute myeloid leukemia (AML) and/or other malignancies/pre-malignancies) of luspatercept in subjects who have participated in other luspatercept clinical trials.Secondary…
The primary objective is to develop algorithms that define digital biomarkers for disease progression in Progressive Supranuclear Palsy patients. The biomarkers, when developed systematically, can eventually serve as primary or secondary clinical…